In a groundbreaking advance poised to reshape the battle against multidrug-resistant bacterial infections, researchers have developed an innovative genetic selection system that bypasses traditional antibiotic markers, enabling real-time, noninvasive imaging of lethal pathogens within living hosts. This breakthrough paves the way for crucial insights into the behavior and treatment response of one of the world’s most formidable hospital-acquired infections: carbapenem-resistant Acinetobacter baumannii (CRAb). The study, recently published in the Journal of Antibiotics, showcases how leveraging non-antibiotic resistance genes coupled with near-infrared bioluminescence technology can revolutionize infection tracking and antibiotic efficacy evaluation in vivo.
Carbapenem-resistant Acinetobacter baumannii is designated a critical priority pathogen by the World Health Organization due to its staggering resistance to multiple antibiotics, particularly carbapenems, which are often considered last-resort treatments. The stubborn resilience of these bacteria, commonly encountered in intensive care units, complicates therapeutic efforts and drastically increases mortality rates worldwide. However, until now, developing effective in vivo models for studying such multidrug-resistant Acinetobacter baumannii (MDRA) isolates has been hampered by the incompatibility of conventional antibiotic selection systems with research on antibiotic efficacy, creating a significant obstacle in translational microbial pathogenesis and pharmacodynamics.
Traditionally, genetic manipulation of bacterial pathogens has relied on antibiotic resistance genes as selection markers within plasmids, facilitating the maintenance and expression of genetic material in experimental infections. While effective for susceptible strains, this approach becomes confounded when applied to multidrug-resistant strains, where endogenous resistance already exists, and further antibiotic pressure invalidates susceptibility testing. To circumvent this challenge, the research team ingeniously swapped antibiotic resistance markers for tellurite resistance genes on a plasmid encoding firefly luciferase — a bioluminescent reporter enzyme that emits light upon oxidation of its substrate.
Tellurite, a toxic metalloid, exerts selective pressure but does not interfere with conventional antibiotic susceptibility profiles, thus providing an orthogonal selection mechanism. This clever substitution enabled stable plasmid maintenance across various clinical MDRA isolates without altering their intrinsic resistance characteristics. The augmented bacteria express luciferase constitutively, allowing them to emit bioluminescent signals that can be detected and quantified in real time, thus transforming invisible infections into vividly trackable events within live animal models.
Utilizing a mouse pneumonia model, a clinically relevant proxy for human respiratory infections, the researchers infected mice with these luminescent MDRA strains to monitor lung colonization noninvasively. Central to this imaging innovation is the deployment of TokeOni, a near-infrared luciferin derivative optimized for deep tissue penetration and low background autofluorescence, making it ideal for in vivo applications. Injected into the infected mice, TokeOni serves as the substrate for luciferase, producing near-infrared luminescence that can be captured externally by sensitive imaging systems, effectively creating glowing maps of microbial burdens within the lungs.
This real-time visualization offers unprecedented granularity in assessing dynamic bacterial proliferation and clearance during therapeutic interventions. Importantly, the intensity and temporal progression of luminescent signals reflected the in vitro minimum inhibitory concentration (MIC) values of administered antibiotics, intricately mirroring therapeutic efficacy. Mice treated with high-efficacy antibiotics displayed rapid declines in lung luminescence, whereas suboptimal treatments or resistant profiles maintained or increased bioluminescent signatures, thereby providing a direct and quantifiable readout of treatment outcomes.
Beyond its immediacy as a diagnostic tool, this platform addresses a critical bottleneck in multidrug-resistant pathogen research — the inability to accurately study pathogen behavior and drug response in vivo without compromising the bacteria’s resistance profiles. By eliminating antibiotic resistance markers from the selection process, this system preserves the native drug susceptibility of clinical strains, thereby enabling authentic evaluation of novel antimicrobial agents and therapeutic regimens in living hosts. This fidelity is essential for advancing preclinical drug development pipelines and for accurately modeling infection biology.
The implications of this advancement extend far beyond Acinetobacter baumannii. The modularity of using tellurite resistance as a non-antibiotic genetic selection marker, combined with luminescent imaging technology, opens avenues for application across a spectrum of multidrug-resistant bacterial species. This is particularly significant given the expanding global threat posed by antimicrobial resistance, which jeopardizes the efficacy of existing drugs and challenges public health infrastructures. Innovative methodologies, such as this, provide critical tools to accelerate the development of next-generation antimicrobials.
Moreover, the near-infrared bioluminescent system offers several advantages compared to other imaging modalities. Its noninvasive nature minimizes animal suffering and reduces the number of subjects required for statistically robust experiments. The deep tissue penetration of near-infrared light allows monitoring of infections in anatomically challenging sites such as lungs, abdomen, and beyond. Additionally, the use of luciferase-TokeOni pairing mitigates the confounding effects of tissue autofluorescence and maximizes signal-to-noise ratio, crucial factors for reliable real-time imaging.
The research methodology meticulously validated that the insertion of tellurite resistance genes and luciferase expression did not induce phenotypic changes that could alter bacterial growth kinetics, virulence, or antibiotic susceptibility. This confirms that the luminescent marker system faithfully represents infection dynamics without artifactual interference, underscoring the robustness of this approach for longitudinal studies. Such thorough validation satisfies stringent criteria demanded by translational microbial research and drug development.
Therapeutically, the capability to monitor bacterial loads noninvasively in a live host accelerates the assessment of antimicrobial candidates. Drug dosing, timing, and combinatorial strategies can be optimized more efficiently by observing how infections respond dynamically rather than relying solely on endpoint measurements like bacterial colony counts or survival alone. This level of insight can also illuminate critical windows of therapeutic intervention and shed light on mechanisms underlying treatment failure or persistence.
In summary, this pioneering work artfully marries synthetic biology, microbiology, and optical imaging to confront the escalating menace of multidrug-resistant Acinetobacter baumannii infections. The development of a non-antibiotic genetic selection system coupled with near-infrared in vivo bioluminescence constitutes a powerful platform for both infectious disease research and antimicrobial drug evaluation. It represents a decisive leap forward in our capacity to observe, understand, and ultimately defeat some of the most formidable bacterial adversaries threatening human health.
As antimicrobial resistance continues to erode our therapeutic arsenals, innovations like this offer a beacon of hope. By equipping researchers and clinicians with sharper tools to visualize infections in real time and with greater fidelity, this technology accelerates the journey toward discovering new antibiotics and refining treatment protocols. This progress not only enhances scientific understanding but directly contributes to saving lives in a world increasingly imperiled by drug-resistant pathogens.
Subject of Research: Multidrug-resistant Acinetobacter baumannii infection models and in vivo imaging evaluation of antibiotic efficacy.
Article Title: A non-antibiotic genetic selection system enables near-infrared in vivo imaging and evaluation of antibiotic efficacy for multidrug-resistant Acinetobacter baumannii.
Article References:
Yamaguchi, D., Kamoshida, G., Asami, T. et al. A non-antibiotic genetic selection system enables near-infrared in vivo imaging and evaluation of antibiotic efficacy for multidrug-resistant Acinetobacter baumannii. J Antibiot (2026). https://doi.org/10.1038/s41429-026-00910-6
Image Credits: AI Generated
DOI: 17 March 2026
Tags: alternative selection markers in microbiologyantibiotic efficacy evaluation in vivoantibiotic resistance mechanism studycarbapenem-resistant Acinetobacter baumanniihospital-acquired infection researchimaging multidrug-resistant bacteriain vivo infection trackingmultidrug-resistant bacterial modelsnear-infrared bioluminescence technologynon-antibiotic genetic selectionnoninvasive pathogen imagingreal-time bacterial monitoring
